Article
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Hepatology (Baltimore, Md.) - 1 Mar 2015
Lawitz Eric, Poordad Fred, Brainard Diana M, Hyland Robert H, An Di, Dvory-Sobol Hadas, Symonds William T, McHutchison John G, Membreno Fernando E
Abstract excerpt
UNLABELLED: Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates. We assessed the efficacy and safety of sofosbuvir plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.